Contents lists available at ScienceDirect

# **Regulatory Peptides**

journal homepage: www.elsevier.com/locate/regpep

# Des-aspartate-angiotensin I attenuates ICAM-1 formation in hydrogen peroxide-treated L6 skeletal muscle cells and soleus muscle of mice subjected to eccentric exercise

Meng-Kwoon Sim<sup>a,\*</sup>, Yong-Chiat Wong<sup>a</sup>, Xiao-Guang Xu<sup>a</sup>, Weng-Keong Loke<sup>b</sup>

<sup>a</sup> Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore

<sup>b</sup> Agent Diagnostics and Therapeutics Laboratory, Defense & Environmental Research Institute, DSO National Laboratories, 11 Stockpark Road, 117605, Singapore

# A R T I C L E I N F O

Article history: Received 14 February 2013 Received in revised form 9 November 2013 Accepted 4 December 2013 Available online 13 December 2013

Keywords: Skeletal muscle damage Des-aspartate-angiotensin l ICAM-1 Superoxide Eccentric exercise Soleus muscle

# ABSTRACT

L6 skeletal muscle cells overexpressed ICAM-1 when treated with  $H_2O_2$ . Maximum effect was observed at 200  $\mu$ M  $H_2O_2$ . Des-aspartate-angiotensin I (DAA-I) concentration-dependently attenuated the overexpression. Maximum attenuation occurred at  $10^{-10}$  M DAA-I.  $H_2O_2$  activated NFkB and its translocation into the nucleus of L6 muscle cells suggesting that NFkB mediates the  $H_2O_2$ -induced overexpression of ICAM-1. DAA-I inhibited the activation and translocation of NFkB.  $H_2O_2$  is a major oxidant formed during skeletal muscle contraction and is implicated in oxidative stress and skeletal muscle damage in excessive unaccustomed exercise. The data show that DAA-I has antioxidant action, and its action was further investigated in the soleus muscle of mice subjected to 240 min of eccentric exercise on a rodent treadmill. The eccentric exercise induced superoxide formation and overexpression. Farlier studies show that DAA-I overexpression. Earlier studies show that DAA-I acts as an agonist on the angiotensin AT<sub>1</sub> receptor and elicits responses opposing those of angiotensin II. The present and earlier findings support the recent suggestion that angiotensin II is involved in skeletal muscle damage. These findings open up new avenues for treatment and management of skeletal muscle damage via the interventions of the renin angiotensin system.

© 2013 Elsevier B.V. All rights reserved.

# 1. Introduction

Unaccustomed and excessive strenuous exercise causes skeletal muscle damage. Both in vivo and in vitro studies indicate that reactive oxygen species (ROS) play a critical role in the damage [1–5]. Oxidative stress, structural muscle damage, and muscle inflammation (resulting from the exercise) generate excess ROS that overwhelm cellular antioxidant defenses and cause tissue damage. Paradoxically, elevated ROS are also involved in endurance exercises that impart resistance to excessive exercise-induced muscle damage. The likely cytoprotective proteins that are induced by the ROS during endurance exercise include heat shock protein 70, Mn-SOD [1], and haem oxygenase-1 [6]. These proteins curtailed the potential damage of greater amount of ROS released in subsequent excessive exercises. Hence, there are uncertainties regarding the prophylactic and acute use of antioxidants in reducing oxidative stress, decreasing muscle damage and improving exercise performance [7]. Recent studies have shown that angiotensin II is

involved in skeletal muscle hypertrophy [8], and angiotensin AT<sub>1</sub> receptor blockade or ACE inhibition improves skeletal muscle features in myopathic states [9–12]. These studies show that angiotensin II is involved in the pathology of skeletal muscle damage, and attenuation of its action offers new interventions for skeletal muscle maladies. Desaspartate-angiotensin I (DAA-I), a nine-aminoacid angiotensin peptide, has been shown to attenuate the early inflammatory processes in animal models of diseases in which angiotensin II has been implicated [13–17]. DAA-I has been shown to act as an agonist on the angiotensin AT<sub>1</sub> receptor and its actions are blocked by indomethacin indicating that prostaglandins mediate its actions [13,15–18]. The present study investigated the possible antioxidant actions of DAA-I on L6 muscle cells subjected to oxidative stress, and on soleus muscle of mice subjected to excessive eccentric exercise. As ROS are known to induce intercellular adhesion molecule-1 (ICAM-1) formation in endothelial and epithelial cells, [19,20], ICAM-1 was investigated as a mediator of inflammation in the present study. Ischemia-induced injury caused vascular endothelial cells to express ICAM-1, which recruited leucocytes [21]. The recruited leucocytes extravasated and caused inflammation including the expression of ICAM-I [21]. The role of ICAM-1 in skeletal muscle damage arising from lengthening contraction is less known.







<sup>\*</sup> Corresponding author. Tel.: +65 68743268; fax: +65 68737690. E-mail address: phcsimmk@nus.edu.sg (M.-K. Sim).

<sup>0167-0115/\$ -</sup> see front matter © 2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.regpep.2013.12.003

#### 2.1. Cell culture

L6 skeletal muscle cells (CRL-1458) were purchased from American Type Culture Collection (ATCC) Maryland, USA. The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; ATCC, 30–2002) containing 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 10% fetal calf serum. The cells were grown to confluence in 25 cm<sup>2</sup> flasks (Nunc, EW-01930-48).

#### 2.2. H<sub>2</sub>O<sub>2</sub> incubation and ICAM-1 determination

L6 skeletal muscle cells were incubated in culture medium containing various concentrations of  $H_2O_2$  (50–1600  $\mu$ M). Cells were then prepared for ICAM-1 determination as described previously [22]. Briefly, cells from each sample were washed, trypsinized, transferred to 2-ml microtubes and treated with anti-ICAM-1 antibody (sc-1151-R, Santa Cruz, CA) for 45 min at ambient temperature. After washing, the cells were further incubated with FITC-conjugated secondary antibody (sc-2090, Santa Cruz, CA). Cells were similarly washed to remove unbound secondary antibody. The cells were counted using a hemocytometer, and diluted with PBS to a concentration of 10<sup>6</sup> cells per ml, and cell fluorescence (at 494 nm excitation and 518 nm emission) quantified by flow cytometry (Beckman CyAn/538R, Beckman Coulter, London, UK). The data were analyzed using the instrument software (SUMMIT 4.3.02). The effects of DAA-1 on the H<sub>2</sub>O<sub>2</sub>-treated L6 muscle cells were studied by incubating the muscle cells with various concentrations of DAA-I for 16 h prior to and during H<sub>2</sub>O<sub>2</sub> incubation.

#### 2.3. Nuclear extraction and Western blot assay

L6 muscle cells were incubated in culture medium containing 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> for various time duration (1, 2, and 3 h). The cells were collected and subjected to nuclear extraction. Briefly, the cells were dissolved in a lysis buffer containing 10 mM HEPES/NaOH (pH 7.9), 1 mM MgCl2, 10 mM KCl, 1 mM dithiothreitol (DTT) and 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and set on ice for 10 min. The lysate was centrifuged at 10,000  $\times$ g for 15 s, and the nucleus-containing pellet was reconstituted in a buffer containing 10 mM HEPES/NaOH (pH 7.9), 25% glycerol, 5 mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM DTT and 0.1 mM PMSF. The nucleus fraction was then put on the ice for 15 min, and centrifuged at 10,000  $\times$ g for 5 min. The supernatant was collected and was stored at -70 °C. Activated NF-KB that had translocated into the nucleus was determined by Western blot. Each isolated nuclear fraction (40 µg) was resolved by SDS-PAGE and probed with anti-NF-KB antibody (sc-109, Santa Cruz, CA), anti-lamin a/c antibody (sc-20681, Santa Cruz, CA), anti-β-actin antibody (sc-130656, Santa Cruz, CA) and anti-rabbit secondary antibody (sc-2004, Santa Cruz, CA). The specific nuclear protein lamin a/c was assayed to determine the purity of the isolated nuclear fraction, and cytoplasmic protein  $\beta$ -actin to determine the contamination by cytoplasmic protein.

## 2.4. Animals and DAA-I

Ten to 12-week-old male C57BL/6J mice (22–24 g) were purchased from the Laboratory of Animal Care, National University of Singapore. All animal procedures were carried out in accordance with Institutional Protocols and Guidelines approved by the National University of Singapore and the Institutional Animal Use and Care Committee (Reference No. IACUC 010/10).

DAA-I was purchased from Bachem AG (Bubendorf, Switzerland). 1-ml aliquots of stock solution (1 mM) were prepared and kept frozen at -20 °C. Working solutions were prepared from the stock solution and filtered (with a 22-µm filter) on the day of use.

#### 2.5. Eccentric treadmill running

The protocol was adapted from the experiment described by Armand et al. [23]. Briefly, 20 mice were trained to run down an incline of 14° on a motor-driven rodent treadmill at 6 m/min for 1 h on day 1, and 9 m/min for 1 h on day 2. On the third day, 16 of the trained mice were selected based on their ability to run continuously during the training sessions without electric shock prodding. The selected mice were divided into two groups of 8 mice. Mice in one group were orally administered 0.2 nmole/kg DAA-I in 0.1 ml water (treated group). This was done by preparing three solutions containing 0.2 nmole/kg DAA-I in 0.1 ml for mice of 22, 23, and 24 g weight, respectively. Mice in the other group were similarly administered 0.1 ml water (control group). Following the administration of either DAA-I or water, the animals were then made to run down the same incline for a total of 240 min. The speed and duration during the 240 min run were 6 m/min for 40 min, 10 m/min for 30 min, 15 m/min for 110 min, and 12 m/min for 60 min. After the exercise, the mice were returned to their cage and were similarly administered with DAA-I or water on day 1 and day 2 post-exercise. On the third day, the mice were sacrificed by cervical dislocation and the soleus muscles were removed and immediately frozen in liquid nitrogen and stored at -70 °C. Sixteen untrained mice of matched weight were also sacrificed and the soleus muscles were similarly frozen.

With the two days of training, all mice were able to complete the eccentric exercise on the third day, which ensured that the animals had the same amount of injurious exercise. Preliminary experiment with an early batch of 4 mice showed that the two-day training session did not cause any significant increase in superoxide level in the soleus muscle of these mice as compared to untrained mice (data not shown), and was unlikely to cause adaptation. Adaptation had been reported to occur when mice ran at a speed of 13 m/min for 60 min per day for



**Fig. 1.** Effect of  $H_2O_2$  on ICAM-1 expression in L6 skeletal muscle cells. L6 muscle cells were exposed to various concentration of  $H_2O_2$  (50–1600  $\mu$ M) for 4 h, and data were collected from at least 10,000 gated viable cells by flow cytometry. Upper panel: Tracing of flow cytometric fluorescence of L6 muscle cells in the absence (Control, left tracing) and presence (right tracing) of 200  $\mu$ M  $H_2O_2$ . Lower panel: Histograms of ICAM-1 fluorescence cells. Each value is the mean  $\pm$  SEM. of three separate experiments. \* Significantly different from the control value (p < 0.05, one-way ANOVA, post hoc Tukey's test).

4 weeks [24] and at a speed of 12–17 cm/s for 75–135 min per day for 9 days [25].

#### 2.6. In situ detection of superoxide

The study was carried out as described earlier [16]. Briefly, each frozen soleus muscle was mounted with Tissue Freezing Medium (Leica, Germany) onto a specimen block. The mounted samples were allowed to cool in a cryostat (Leica CM 3050S) for 10 min at -28 °C, before cutting into 20 µm-thick sections and picked up onto gelatin-coated slides. The slides were warmed in room temperature for 30 min and fixed in cold acetone for 2 min. After fixation, the slides were washed with PBS and allowed to air-dry in room temperature for 1 h. Each sample was incubated with 2 µmol/L dihydroethidium solution (Biotium, CA) for 30 min at 37 °C. Dihydroethidium is oxidized in the presence of superoxide to form ethidium, which binds specifically to DNA in the nucleus and emits red fluorescence. In situ detections of superoxide in the muscle tissues of the treated animals were then carried out using fluorescence microscope and the intensity was quantified using Imaging software (Image Processor, New York University).

# 2.7. Western blot determination of ICAM-1

Each pair of soleus muscle (~0.2 g) was minced on an ice pack and homogenized in 10 volume (w/v) of CellLytic MT mammalian tissue lysis reagent and 1% protease inhibitor cocktail (Sigma Chemical, St. Louis, MO) in a Potter-Elvehjem homogenizer immersed in crushed ice for 1 min. The homogenate was incubated on ice for 50 min, and centrifuged at 10,000 ×g for 10 min. The supernatant was stored at -70 °C till used. Protein concentration of the muscle supernatant was determined by Bio-Rad protein assay (Bio-Rad Laboratories, Hercules,



**Fig. 2.** Effects of DAA-1 on H<sub>2</sub>O<sub>2</sub>-induced overexpression of ICAM-1 in L6 skeletal muscle cells. Upper panel: Tracing of flow cytometric fluorescence of L6 muscle cells. The tracings for the Control, and cells treated with of 200  $\mu$ M H<sub>2</sub>O<sub>2</sub> were copied from Fig. 1. Left-hatched tracing was from H<sub>2</sub>O<sub>2</sub>-treated cells in the presence of 10<sup>-10</sup> M DAA-I. Lower panel: Histograms of ICAM-1 fluorescence cells. Each value is the mean  $\pm$  SEM. of three separate experiments. \* Significantly different from the value of H<sub>2</sub>O<sub>2</sub>-treated cells (p < 0.05, one-way ANOVA, post hoc Tukey's test).



Fig. 3. Effects of DAA-1 on H<sub>2</sub>O<sub>2</sub>-induced activation and translation of NF- $\kappa$ B to the nucleus in L6 skeletal muscle cells. Upper panel: representative Western blot of activated NF- $\kappa$ B protein,  $\beta$ -actin, and lamin a/c. Lower panel: Ratio of densitometric reading of NF- $\kappa$ B protein/lamin a/c. each value is the mean  $\pm$  SEM. of three separate experiments. \* Significantly different from the corresponding value, cells incubated with H<sub>2</sub>O<sub>2</sub> for 3 h (p < 0.05. one way ANOVA, post hoc Tukey's test).

CA). Samples of muscle supernatant (0.2 mg protein) were resolved by electrophoresis in 10% SDS-PAGE polyacrylamide gel, for 120 min at 100 V, before transfer to nitrocellulose polyvinylidene difluoride (PVDF) membranes (Sigma Chemical, St. Louis, MO). Membranes were then blocked with 5% BSA at room temperature for 1 h, before incubation with mouse monoclonal ICAM-1 antibody (Sigma Chemical, St Louis, MO) in a 1:200 dilution with 5% BSA solution overnight, at 4 °C. For negative control, membranes were incubated with PBS instead of monoclonal ICAM-1 antibody. Membranes were then rinsed in three changes of 0.1% Tween in TBS (TBS-T), each step lasting 10 min. Membranes were incubated with horseradish peroxidase conjugated donkey anti-mouse secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) in a 1:10,000 dilution in TBS, for 1 h at room temperature before rinsing in 3 changes of TBS-T, each step lasting 10 min. Signal was developed by direct exposure of the PVDF membrane in 200 µl of Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) for 1 min in a gel imager (Gel Doc Ez, Bio Rad Laboratories).

## 2.8. Statistics

Data were expressed as means  $\pm$  SEM. Vertical error bars in figures denote the SEM. Statistical analysis for significant differences between groups was performed using analysis of variance (ANOVA), with posthoc Tukey's test. A p-value of less than 0.05 was considered statistically significant.

#### 3. Results

# 3.1. DAA-I attenuates ICAM-1 formation in H<sub>2</sub>O<sub>2</sub>-treated L6 muscle cells

Preliminary experiments showed that, within the concentration range used in Figs. 1 and 2, both  $H_2O_2$  and DAA-I had no effect on the



**Fig. 4.** Effect of DAA-I on ROS production in skeletal muscle of mice subjected to eccentric exercise. Upper panel: Ethidium fluorescence of skeletal muscle cryosections. Lower panel: Fluorescence densitometry of cryosections. Each value represents the mean  $\pm$  SEM. of 4 individual animals. \* Significantly different from the value of eccentric exercised-mice that were treated with vehicle (p < 0.05. one way ANOVA, post hoc Tukey's test).

viability of L6 muscle cells (data not shown).  $H_2O_2$  induced overexpression of ICAM-1 in L6 muscle cells. The induction was concentration dependent and maximum effect was observed with a concentration of 200  $\mu$ M  $H_2O_2$  (Fig. 1). DAA-I attenuated the overexpression of ICAM-1 in L6 muscle cells treated with 200  $\mu$ M  $H_2O_2$ . Maximum attenuation was observed at  $10^{-10}$  M DAA-I, and significant attenuation was seen with concentration as low as  $10^{-16}$  M (Fig. 2). The action of DAA-I at such low concentrations was also seen in earlier in vitro studies [26,27], and could be due to the possibility that circulating DAA-I (present in pmolar range; [28]) was active physiologically. The tissue level of active DAA-I could be much lower than the circulating level.

The procedure used in nuclear extraction yielded a nuclear fraction that had negligible cytoplasmic contamination (Fig. 3). The activation and translocation of NF- $\kappa$ B to the nucleus occurred in L6 skeletal muscle cells treated with 200  $\mu$ M H<sub>2</sub>O<sub>2</sub>, and 10<sup>-10</sup> M DAA-I significantly attenuated both processes (Fig. 3).

# 3.2. DAA-I attenuates eccentric exercise-induced superoxide and ICAM-1 formation in skeletal muscles

Eccentric exercise of 240-min duration generated superoxide formation in soleus muscle of the mouse. The formation was attenuated by DAA-I, and an oral dose of 0.2 nmole/kg produced the maximum effect (Fig. 4). Soleus muscle also over-expressed ICAM-1 protein following similar eccentric exercise, and an oral dose of 0.2 nmole/kg significantly attenuated the over-expression (Fig. 5). Constitutively expressed ICAM-1 in skeletal muscle was barely detectable by the Western blot employed in this study. Similar observations have also been reported by other investigators using different protocols [29,30].

#### 4. Discussion

In the present study, the treatment of L6 muscle cell with  $H_2O_2$ , a major ROS in skeletal muscle [31], caused overexpression of ICAM-1, an early inflammatory protein involved in the recruitment of leucocytes. The concurrent activation and translocation of NF- $\kappa$ B to the nucleus



**Fig. 5.** Effects of DAA-I on the expression of ICAM-1 protein in skeletal muscle of mice subjected to eccentric exercise. Upper panel: Representative Western blots of ICAM-1 protein. Lower panel: Density ratio of ICAM-1/actin. Each value represents the mean  $\pm$  SEM. of four animals. \* Significantly different from the value of eccentric exercised-mice that were treated with vehicle (p < 0.05, one way ANOVA, post hoc Tukey's test).

were also observed, and this supports the contention that NF- $\kappa$ B is a major nuclear transcriptional activator that mediates the action of ROS [32], and the overexpression of ICAM-1 observed in the L6 muscles cells. Similar findings on these two actions of H<sub>2</sub>O<sub>2</sub> have also been reported [4,5]. DAA-I inhibited both the translocation of NF- $\kappa$ B to the nucleus and overexpression of ICAM-1 indicating that the nonapeptide could be an effective antioxidant in combating oxidative stress in skeletal muscles. This possibility was investigated in mice that had undergone excessive eccentric exercise on a rodent treadmill.

The protocol of the eccentric exercise was designed to induce increase in superoxide (precursor of ROS) production and overexpression of ICAM-1 in the soleus muscle of the mice. Preliminary experiments showed that maximum production of superoxide and ICAM-1 occurred on the third day after eccentric exercise. This duration is in accordant with findings showing that initial mechanical injury in skeletal muscles initiates a cascade of events that lead to more severe late onset injury that peaks in rodents at approximately day 3 post exercise [33–36]. DAA-I attenuated both the superoxide production and overexpression of ICAM-I in soleus muscle at day 3 post exercise. This finding is a first demonstration of an antioxidant and inflammatory action DAA-I in late onset skeletal muscle damage arising from eccentric exercise. Antioxidant like polyethylene glycol-superoxide dismutase has also been shown to protect mouse muscle from late onset injury caused by plyometric contractions [34]. In vitro L6 muscle cell experiments show that DAA-I directly attenuates the action of ROS, and this could also occur in the soleus muscle resulting in the observed reduced formation of ICAM-1. DAA-I has been shown to attenuate the upregulation of gp91 subunit of NADPH oxidase in skeletal muscle of hyperglycemic mice, and lung of mice that were exposed to half sulfur mustard intoxication resulting in the reduction of ROS formation in these two tissues [16,37]. It is also likely that DAA-I could act to curtail the upregulation of NADPH oxidase as membrane-bound enzymes in skeletal muscles have been suggested to generate superoxide in contractile activity-induced oxidative stress [38]. ICAM-1 appears to be an important molecule involved in skeletal muscle injury and disease. Ischemia-induced injury caused vascular endothelial cells in mouse skeletal muscle to express ICAM-1, which recruited leucocytes. The recruited leucocytes transmigrated and caused inflammation including the expression of ICAM-I in skeletal muscle cells [39]. Acute prolonged exercise caused delayed-onset skeletal muscle damage in the rat and this is related to inflammation via phagocyte infiltration caused by ROS [4]. However, there is a paucity of information on the role of ICAM-1 in skeletal muscle damage arising from lengthening contraction; and avenues of therapeutic interventions on this molecule await further investigation.

As shown in Figs. 2 and 4, the action of DAA-I was less effective at concentrations higher than the maximal effective concentration, but this profile was also characteristic of other DAA-I activities [15-17,22,40]. Although the exact mechanism for this biphasic phenomenon is not known, it could be a hormetic response [41] that involves receptor down-regulation by different mechanisms at high doses of DAA-I [42-44]. DAA-I being an endogenous angiotensin could also, at higher doses, bind to the classical angiotensin II inositol triphosphate-generating AT<sub>1</sub> receptor and annul its more specific action mediated by the indomethacin-sensitive receptor. The possibility is supported by earlier findings showing that DAA-I produced differential responses in adjacent sections of the rabbit pulmonary artery. DAA-I produced contraction in the pulmonary end of the artery and relaxation in the cardiac end of the artery. The contraction was inhibited by losartan but not indomethacin, while the relaxation was inhibited by both losartan and indomethacin [18].

Evidence for the involvement of angiotensin II in skeletal muscle damage comes from the study by Bedair et al. [45]. They showed that injured skeletal muscles had more angiotensin AT<sub>1</sub> receptors than normal muscles, and losartan significantly reduced fibrosis and increased the number of regenerating myofibers in acutely injured skeletal muscles of the mouse. Other studies showed that ACE inhibitors improved

muscular performance and decreased rate of muscle wasting in hypertensive patients [46], and enalapril was able to blunt angiotensin II-dependent activation of pro-inflammatory and pro-oxidant pathways in exercised dystrophic mdx mice [12]. Both losartan and ACE inhibitors curtail that activity of angiotensin II, albeit by different mechanisms, the former by blocking the angiotensin AT<sub>1</sub> receptor and the latter by inhibiting the formation of angiotensin II from angiotensin I. Earlier studies show that DAA-I acts as an agonist on the angiotensin AT<sub>1</sub> receptor and exerts actions opposing those of angiotensin II [27,47,48]; and ameliorates symptoms in diseases in which angiotensin II is implicated [13–15,17,37]. DAA-I together with losartan (and possibly other angiotensin receptor blockers) and ACE inhibitors could be considered a new class of drug that protects or ameliorates skeletal muscle damage by curtailing the actions of angiotensin II. They offer potential new approaches and open up new avenues of research in sport injuries and muscle deterioration in the elderly.

#### Acknowledgment

The study was supported by a combined grant from the Defense Science & Technology Agency (Singapore) and the National University of Singapore, Grant MINDEF-NUS-JPP/09/05.

#### References

- Sachdev S, Davies KJA. Production, detection, and adaptive responses to free radicals in exercise. Free Radic Biol Med 2008;44:215–23.
- [2] Maruhashi Y, Kitaoka K, Yoshiki Y, Nakamura R, Okano A, Nakamura K. ROS scavenging activity and muscle damage prevention in eccentric exercise in rats. J Physiol Sci 2007;57:211–6.
- [3] Kerkweg U, Petrat F, Korth H-G, de Groot H. Disruption of skeletal myocytes initiates superoxide release: contribution of NAD(P)H oxidase. Shock 2007;27:552–8.
- [4] Aoi W, Naito Y, Takanami Y, Kawai Y, Sakuma K, Ichikawa H, et al. Oxidative stress and delayed-onset muscle damage after exercise. Free Radic Biol Med 2004;37:480–7.
- [5] Sen CK, Khanna S, Reznick AZ, Royh S, Packer L. Glutathione regulation of tumor necrosis factor-α-induced NF-κB activation in skeletal muscle-derived L6 cells. Biochem Biophys Res Commun 1997;237:645–9.
- [6] McArdle A, Pattwell D, Vasilaki A, Griffiths RD, Jackson MJ. Contractile activityinduced oxidative stress: cellular origin and adaptive responses. Am J Physiol Cell Physiol 2001;280:C621–7.
- [7] Petermelj T-T, Coombes JS. Antioxidant supplementation during exercise training. Sports Med 2011;42:1043–69.
- [8] Gordon SE, Davis BS, Garlson CJ, Booth FW. ANG II is required for optimal overloadinduced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab 2001;280:150–9.
- [9] Cabello-Verrugio C, Moraies MG, Cabrera D, Vio CP, Brandan E. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J Cell Mol Med 2012;16:752–64.
- [10] Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13:204–10.
- [11] Gharaibeh B, Chun-Lansinger Y, Hagen T, Ingham SJ, Wright V, Fu F. Biological approaches to improve skeletal muscle healing after injury and disease. Birth Defects Res C Embryo Today 2012;96:82–94.
- [12] Cozzoli A, Nico B, Sblendorio VT, Capogrosso RF, Dinardo MM, Longo V. Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res 2011;64:482–92.
- [13] Sim MK, Min L. Effects of des-Asp-angiotensin I on experimentally-induced cardiac hypertrophy in rats. Int J Cardiol 1998;63:223–7.
- [14] Sim MK, Tang FR, Xu XG. Effects of des-aspartate-angiotensin I on neointima growth and cardiovascular hypertrophy. Regul Pept 2004;117:213–7.
- [15] Wen Q, Sim MK, Tang FR. Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart. Regul Pept 2004;120:149–53.
- [16] Ng ETL, Sim MK, Loke WK. Protective actions of des-aspartate-angiotensin I in mice model of CESS-induced lung intoxication. J Appl Toxicol 2011;31:568–78.
- [17] Wen Q, Sim MK. Effects of des-aspartate-angiotensin I on myocardial ischemiareperfusion injury in rats. Eur J Pharmacol 2011;658:193–9.
- [18] Sim MK, Chai SK. Subtypes of losartan-sensitive angiotensin receptor in the rabbit pulmonary artery. Br J Pharmacol 1996;117:1504–6.
- [19] Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876–88.
- [20] Kim H, Hwang J-S, Woo C-H, Kim E-Y, Kim T-H, Cho K-J, et al. TNF-α-induced up-regulation of intercellular adhesion molecule-1 is regulated by a Aac-ROsdependent cascade in human airway epithelial cells. Exp Mol Med 2008;40:1–175.
- [21] Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31–47.

- [22] Ang LT, Tan LY, Chow VT, Sim MK. Des-aspartate-angiotensin I exerts antiviral effects and attenuates ICAM-1 formation in rhinovirus-infected epithelial cells. Eur | Pharmacol 2012;683:310–5.
- [23] Armand AS, Launay T, Della Caspera B, Charbonnier F, Gallen GL, Chanoline C. Effects of eccentric treadmill running on mouse soleus: degeneration/regeneration studied with Myf-5 and MyoD probes. Acta Physiol Scand 2003;179:75–84.
- [24] Lynch GS, Fary CJ, Williams DA. Quantitative measurement of resting skeletal muscle [Ca<sup>2+</sup>], following acute and long-term downhill running exercise in mice. Cell Calcium 1997;22:363–83.
- [25] Hody S, Lacrosse Z, Leprince P, Collodoro M, Croisier J-L, Rogister B. Effects of eccentrically and concentrically biased training on mouse muscle phenotype. Med Sci Sports Exerc 2013;45:1460–8.
- [26] Mustafa MR, Dharmani M, Kunheen NK, Sim MK. Effects of des-aspartateangiotensin I on the actions of angiotensin III in the renal and mesenteric vasculature of normo- and hypertensive rats. Regul Pept 2004;120:15–22.
- [27] Dharmani M, Mustafa MR, Achike FI, Sim MK. Effect of des-aspartate-angiotensin I on the actions of angiotensin II in the isolated renal and mesenteric vasculature of hypertensive and STZ-induced diabetic rats. Regul Pept 2005;129:213–9.
- [28] Sim MK, Qui XS. Angiotensins in plasma of hypertensive rats and human. Regul Pept 2003;111:179–82.
- [29] Kearns SR, Daly AF, Sheehan K, Murray P, Kelly C, Bouchier-Hayes D. Oral vitamin C reduces the injury to skeletal muscle caused by compartment syndrome. J Bone Joint Surg Br 2004;86:906–11.
- [30] Anderson SI, Shiner R, Brown MD, Hudlicka O. ICAM-1 expression and leukocyte behaviour in the microcirculation of chronically ischemic rat skeletal muscles. Microvasc Res 2006;71:205–11.
- [31] Jackson MJ. Control of reactive oxygen species production in contracting skeletal muscle. Antioxid Redox Signal 2011;15:2477–86.
- [32] Muller JM, Rupec RA, Baeuerle PA. Study of gene regulation by NF+6B and AP-1 in response to reactive oxygen intermediates. Methods 1997;11:301–12.
- [33] McCully KK, Faulkner JA. Injury to skeletal muscle fibers of mice following lengthening contractions. J Appl Physiol 1985;59:119–26.
- [34] Zerba E, Komorowski TE, Faulkner JA. Free radical injury to skeletal muscles of young, adult, and old mice. Am J Physiol 1990;258:C429–35.
- [35] van der Meulen J, Jackson MJ, Faulkner JA. Contraction-induced injury to the extensor digitorum longus muscles of rats: the role of vitamin E. J Appl Physiol 1997;83:817–23.

- [36] McArdle A, van der Meulen JH, Catapano M, Symons MCR, Faulkner JA, Jackson MJ. Free radical activity following contraction-induced injury to the extensor digitorum longus muscles of rats. Free Radic Biol Med 1999;26:1085–91.
- [37] Wong YC, Sim MK, Lee KO. Des-aspartate-angiotensin I and angiotensin IV improve glucose tolerance and insulin signaling in diet-induced hyperglycemic mice. Biochem Pharmacol 2011;82:1198–208.
- [38] McArdle F, Spiers S, Aldemir H, Vasilaki A, Beaver A, Iwanejko L. Preconditioning of skeletal muscle against contraction-induced damage: the role of adaptations to oxidants in mice. J Physiol 2004;561:233–44.
- [39] Merchant SH, Curule DM, Larson RS. Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of ICAM-1. Am J Physiol Heart Circ Physiol 2003;294: H1260–8.
- [40] Sim MK, Xu XG, Wong YC, Sim SZ, Lee KO. Des-aspartate-angiotensin I exerts hypoglycemic action via glucose transporter-4 translocation in type 2 diabetes KKAy mice and GK rats. Endocrinology 2007;148:5925–32.
- [41] Mattson M. Hormesis defined. Ageing Res Rev 2008;7:1–7.
- [42] Bohm SK, Grady EF, Bunnett NW. Regulatory mechanisms that modulate signaling by G-protein-coupled receptor. Biochem J 1997;322:1–18.
- [43] Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205–51.
- [44] Zhang J, Ferguson SS, Barak LS, Ménard L, Caron MG. Dynamin and β-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J Biol Chem 1996;271:18302–5.
- [45] Bedair HS, Karthikeyan T, Quintero A, Li Y, Huard J. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle. Am J Sports Med 2008;36:1548–54.
- [46] Onder G, Penninx BW, Blakrishnan R, Fried LP, Chaves PH, Willianson J. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002;359:926–30.
- [47] Sim MK, Radhakrishnan R. Novel central action of des-Asp-angiotensin I. Eur J Pharmacol 1995;257:R1–3.
- [48] Min I, Sim MK, Xu XG. Effects of des-aspartate-angiotensin I on angiotensin II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells. Regul Pept 2000;95:93–7.